PRESS RELEASE

Temedica expands its Advisory Board with former Gematik CEO Markus Leyck Dieken

• Dr. med. Markus Leyck Dieken, former CEO of Gematik, joins the Advisory Board of Temedica.
• Dr. Leyck Dieken is recognized as an innovator and leading figure in the digital transformation of healthcare and brings profound experience from the life sciences industry.

Munich, May 16, 2024 – The Munich-based health insights company Temedica announces the addition of Dr. med. Markus Leyck Dieken as a new member of its Advisory Board. The former Gematik CEO will particularly advise Temedica on strategic-regulatory issues. He is a seasoned expert with many years of clinical experience as a specialist in internal and emergency medicine, combined with 25 years in the biotech industry, where he worked in the development, production, and marketing of biotechnological products, including vaccines and biosimilars.
 

Gloria Seibert, CEO of Temedica, comments on this significant step:

"Adding Dr. Markus Leyck Dieken to our Advisory Board is an immense gain for Temedica. His expertise in market access and reimbursement, as well as his role in political and health policy committees, make him a valued member and will help us further enhance our leading position in the area of real-world evidence and the personalization of medicine."

Leyck Dieken played a central role in the development and market leadership of diabetes therapies at Novo Nordisk, headed the EU vaccine business at Novartis, and founded the first EU subsidiary of the California biotech company InterMune. At Teva Pharmaceuticals, he expanded the range of original preparations and made a significant contribution to combating antibiotic resistance at Shionogi Europe. As CEO of Gematik, Leyck Dieken was significantly involved in the digital transformation of the German healthcare system, particularly through the introduction of electronic health records and digital prescriptions.

Dr. med. Markus Leyck Dieken emphasizes:

"The innovative approach and entrepreneurial drive of Temedica have deeply impressed me. With today's digital capabilities, we can use information in unprecedented ways for research and improving patient care. Therefore, I am pleased to contribute to Temedica and utilize the enormous potential of real-world evidence for the entire industry."

Leyck Dieken is recognized as a long-standing, well-connected partner of many stakeholders and brings valuable international perspectives and a deep understanding of regulatory issues to Temedica.
 

About Temedica

Temedica is a health insights company based in Munich. Since 2016, it operates Europe's leading ecosystem for real-world insights in the healthcare sector. Temedica's mission is to enable personalized and individualized medicine, thereby focusing on patients and their individual needs. The company achieves this by linking health-related data from various sources, which are processed into valuable insights in compliance with the GDPR.

Temedica is backed by a consortium of renowned investors with many years of experience in the biopharmaceutical industry, including the founding investors of BioNTech. For further information, please visit /en/.

For further information and media inquiries, please contact:

Temedica GmbH

Anna Hauner

Corporate Communications

T: 0 1

Email: